retrospective evaluation of hairy cell leukemia patients treated with three different first-line treatment modalities in the last two decades: a single-center experience
Clicks: 233
ID: 160267
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
233 views
30 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #21 of 54 articles by views in proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective: In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases.
Materials and Methods: Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one.
Results: Although the highest overall response rate (ORR) was observed in patients receiving 2-CdA upfront, ORRs were comparable in the 2-CdA, INF-α, and splenectomy subgroups. Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA was significantly higher than in patients with INF-α and splenectomy, but we found similar overall survival rates with all three upfront treatment modalities. Infections including tuberculosis were a major problem.
Conclusion: Although purine analogues have improved the ORRs and PFS, there is still much progress to make with regard to overall survival and relapsed/refractory disease in patients with HCL.
| Reference Key |
ngren2017turkishretrospective
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Şeniz Öngören;Ahmet Emre Eşkazan;Selin Berk;Tuğrul Elverdi;Ayşe Salihoğlu;Muhlis Cem Ar;Zafer Başlar;Yıldız Aydın;Nükhet Tüzüner;Teoman Soysal |
| Journal | proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017 |
| Year | 2017 |
| DOI |
10.4274/tjh.2017.0443
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.